MENU

OUR STORY

Molekule was incorporated with the notion that “good” and the “status quo” were inadequate.

Born out of a vision to create a firm combining an ethos of strategic & actionable competitive insight with industry leading dedication to clients, Molekule Consulting was founded in 2012 by David Alderman.
Molekule seeks to align intelligence outcomes, focus results, and enable our client partners to “win” in a highly dynamic and competitive environment.

Molekule is one of the few competitive intelligence consultancies dedicated solely to the CI space in the biopharmaceutical sector.

THE MOLEKULE WAY

VISION
We aspire to be the premier competitive intelligence and strategy consulting company in the life sciences industry delivering actionable insights and recommendations to our clients, essential for decision making, strategy development, and execution.
We aspire to be the premier competitive intelligence and strategy consulting company in the life sciences industry delivering actionable insights and recommendations to our clients, essential for decision making, strategy development, and execution.
VALUE
Molekule Consulting is a proactive and dedicated partner that leverages its industry leading CI expertise, deep area knowledge and its extensive global network to provide world-class competitive intelligence and strategy services.
Molekule Consulting is a proactive and dedicated partner that leverages its industry leading CI expertise, deep area knowledge and its extensive global network to provide world-class competitive intelligence and strategy services.
GUARANTEE
As a trusted consultant, Molekule conducts its business in an ethical manner with the highest level of integrity. Molekule Consulting will never compromise on these values.
As a trusted consultant, Molekule conducts its business in an ethical manner with the highest level of integrity. Molekule Consulting will never compromise on these values.

Global Presence

The Molekule team has a global footprint with significant “boots on the ground” presence across continents.
Worldwide
Headquarters
Miami, FL
Offices
New York, NY
Europe presence has been built-out to better accommodate our European client base
Headquarters
London, UK
India presence consists of full-time staff supporting our global business
Headquarters
New Delhi, IN

Code of conduct

We commit

Molekule is committed to the highest standard of ethics throughout its global offices and worldwide consulting staff.

WE COMPLY

Molekule strictly complies with all global, regional, national and local laws and regulations pertinent to primary human source intelligence.

WE FOLLOW

Molekule complies with all SCIP rules, regulations and guidelines, globally, across all office locations and human capital resources.

WE EXECUTE

Molekule is committed to quality and integrity in all that we do, from how we safeguard client data to how we strive to continuously improve our performance.

SELECT TEAM PROFILES

Growing from strength to strength, the Molekule team is proud to have 180+ years of combined experience “within-the-walls” of Blue Chip pharma and generics competitive insights functions, including group leadership.
Our team brings with it a depth and breadth of functional, therapy area, and industry expertise that is rare among management consultancies.
David
Alderman
President & CEO
Learn More
Dr. Brett
Alcott
Associate Director
Learn More
Dr. Mridul
Das
Associate Vice President
Learn More
Dr. Paul
Nunzio De Santis
Vice President
Learn More
Dr. Oleh Denysyk
Dr. Oleh
Denysyk
Vice President
Drew
Fussner
Chief Operations Officer
Learn More
Dr. Michael
Marlatt
Chief Compliance Officer & President, Worldwide Research
Dr. Phillip
Murray
Chief of Staff & Vice President
Learn More
Dr. Mark
Powzaniuk
Chief Business Officer
Jayant
Rana
Associate Vice President & Head of India
Learn More
Sharon
Rosaler
Chief Financial Officer
Learn More
Dr. Richa
Sharma
Associate Director
Learn More
Dr. Michael
Shipley
Director
Learn More
Chris Stevenson
Chris
Stevenson
Managing Director, Europe
Learn More
Siddharth
Subramaniam
Associate Director
Learn More
David founded Molekule Consulting with an ethos of strategic and actionable competitive insight combined with client centricity. He is responsible for numerous engagements with varied scopes and objectives in the competitive intelligence and primary market research areas. Project scopes range from pre-clinical through launch and lifecycle management (“LCM”) to supporting clients in clinical and commercial strategy development.
His major therapy expertise is in oncology, ophthalmology, cardiovascular, diabetes, autoimmune, and CNS. David attends numerous major medical congresses and scientific congresses globally.
Therapy Area & Subject Matter Expertise
Competitive Simulation Workshops
Generics & Biosimilars
Pre- & Peri-LoE Strategy
Cardiovascular
Manufacturing & Supply Chain Intelligence
Oncology
Ophthalmology
CDN
Go-to-Market Strategy
Strategic Benchmarking
Immunology & Inflammation
Product & Portfolio Optimization
Chris is an experienced professional service firm leader, and a leader in strategic thinking in healthcare. Chris brings experience in pharma, notably in the global marketing business of Johnson and Johnson where he worked for 11 years, and in multiple professional services firms where Chris has created businesses and highly effective teams.
Chris is a specialist in commercial strategy, and on building successful firms, and has written numerous articles on these topics, and he believes in generating actionable insights that can make a meaningful difference. With global experience across multiple therapy areas Chris provides clients with a broad and evidence based perspective that supports them in building modern, global, brands.
Therapy Area & Subject Matter Expertise
Scenario Planning
Competitive Strategy
Positioning Strategy
Pre-launch and Post launch Market Access Strategy
Oncology
Hematology
Immunology
Gene Therapy
Mental Health
Michael is a uniquely experienced competitive intelligence (CI) professional and therapeutic area expert, who joined Molekule in 2017, where he has since led high-impact engagements across domains. Stylistically, he brings first-hand experience, rigorous attention to delivery, and lateral thinking to the management team and client engagements.
Mike began his career in Neuroscience Drug Discovery at Merck Research Labs. Following a PhD in the same field, completed at the University of Amsterdam and National Institutes of Health, he joined Deallus Consulting and was subsequently recruited to Occam Global, prior to joining Molekule.
Therapy Area & Subject Matter Expertise
Competitive Simulation Workshops
Immunology & Inflammation
Pre- and Peri-LOE Strategy
Regulatory Strategy
Life Cycle Management
Sales Force size structure
Rare Diseases
Diagnostics
Oncology
Virology
CNS
Dr. Mark Powzaniuk joined Molekule Consulting after spending 19 years within the pharmaceutical industry. As a seasoned pharmaceutical professional, he brings a unique background of science and business acumen. His experiences include Basic Research, Project Management, and Finance. Most recently, Mark was head of Global Competitive Intelligence, Oncology at Merck.
Mark started his career as a Post-Doctoral Research Fellow in the Bone Biology Department at Merck. After completing his fellowship, he joined Merck Project Management with increasing roles of responsibility, gaining both clinical and commercial experience. While obtaining his M.B.A., Mark transitioned to Business Integration and Finance. After a successful finance career, Mark joined Competitive Intelligence at Merck.
Therapy Area & Subject Matter Expertise
Competitive Intelligence Strategy and Processes
Oncology
Immuno-Oncology
Vaccine
Business Development and Licensing
Project Management
Competitive Intelligence Strategy & Processes
Life Cycle Management
Neuroscience
Oleh is a skilled competitive and business intelligence professional and a leader with an integrated background in biopharmaceuticals and healthcare. Having played key roles on the client side, he brings a keen knowledge of market and competitive intelligence expected by his clients and their internal partners including senior management. He is responsible for numerous engagements with varied scopes and objectives and assists in leading Strategic Competitive Simulation Workshops for clients. Oleh maintains his pharmacist license in two jurisdictions.
He practiced in hospital, long-term care and retail settings as the Pharmacist In Charge and was invited to join the Rho Chi Pharmacy Honor Society. He brings a holistic approach, using the 5-Forces Model, in obtaining actionable HUMINT (Human Intelligence) to help his clients make key decisions. Oleh is multilingual and attends numerous medical and scientific congresses globally.
Therapy Area & Subject Matter Expertise
Licensing & Business Development
Atypical Antipsychotics
Market Access/ Reimbursement
Endocrinology
Organ Transplantation
Ophthalmology
Autoimmune Diseases
Diagnostics
CNS
Bone Disease
Hematology
Regenerative Medicine
Oncology
Jayant is a CI expert adept in generating market and competitor insights. He joined Molekule in 2016 after significant blue chip pharma experience. At Novartis, Jayant delivered insights to global and country brand teams across the globe in support of multiple blockbuster brands. At Abbott, Jayant supported the leadership team in diverse projects related to SFE, CRM, and business analytics to achieve strategic objectives profitably and sustainably.
At Lilly, Jayant developed market research expertise in support of the Diabetes brand team. By academic training, Jayant is a biotechnology engineer and holds an MBA from the Indian Institute of Foreign Trade (IIFT).
Therapy Area & Subject Matter Expertise
Sales Force Effectiveness
Emerging Markets
Immunology
Generics & Biosimilars
Hematology
Diabetes
Competitive Analysis
Neurology
Respiratory
Cardiology
Mridul is a Director at Molekule Consulting. He started his career as a physician and holds an MBA degree from Amity University and is Six Sigma Green Belt certified from British Standards Institution. After a brief stint at AIIMS, he moved to strategy consulting and spent ten years across various organizations like Deloitte, Global Data, and Smart Analyst.
Therapy Area & Subject Matter Expertise
Business Development & Licensing
Prioritization (Assets & Indications)
Infectious Diseases
Portfolio Management (Optimization)
Competitive Intelligence
Rare Diseases
Commercial Opportunity Assessment
Oncology
Renal Diseases
Phil has a breadth of experience in the fundamental and practical applications of drug development and business strategy. Formally trained in biophysics and biochemistry, Phil has a keen understanding of the biopharma industry including preclinical and early development, new product planning, intellectual property and M&A due diligence, and commercialization from launch through life-cycle management.
Phil holds a Ph.D. in Pharmacology from the Yale School of Medicine, where he received an Excellence in Science Award from the American Academy for the Advancement of Science (AAAS). He received his undergraduate education in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder, and was an Amgen Scholar at the University of California, San Diego.
Therapy Area & Subject Matter Expertise
Immuno-Oncology
CAR-T Cell Therapy
Pharmacology
Clinical & Preclinical Data Analysis
Oncology
Drug Discovery & Design
Therapeutic Antibodies
NGS Technologies & Diagnostics
Drew joined Molekule Consulting after spending 19 years within the pharmaceutical industry. He has a unique breadth of knowledge spanning science, manufacturing, and strategic marketing. He provides insightful market intelligence, product evaluations, and strategic recommendations based on past experiences in portfolio management. Prior to Molekule Drew held progressive roles at Mallinckrodt Pharmaceuticals / Covidien in Strategic Marketing and R&D.
Drew started his career in R&D at Covidien, Pfizer (King), and the U.S. FDA. After completing his M.B.A., he transitioned to Strategic Marketing and was responsible for pipeline product sections, product management, commercial launches, and evaluation of BD&L opportunities as the lead of generic portfolio competitive intelligence.
Therapy Area & Subject Matter Expertise
Generics & Biosimilars
Manufacturing Intelligence
Supply Chain Logistics Intelligence
CNS
Device Combination Products
Portfolio Management / Product Selection
Strategic Planning Cycle
Project Management
Forecasting & Modeling
Dr. Paul De Santis, PharmD joined Molekule Consulting after spending 4 years as a GLG special council member in Immuno-Oncology and Cell Therapy consulting for several of the largest global Private Equity and Hedge Funds with more than $10B in assets under management. During this time clients leveraged his depth of expertise on commercial dynamics operating within the Cell and Gene Therapy landscape to perform deep-dive addressable market analyses and leveraged his clinical expertise to understand an assets probability of regulatory and commercial success in support of valuation analysis.
In addition, he supported pre-commercial planning for several CAR T companies leveraging these skillsets to develop commercialization strategies that can maximize patient access to autologous cell therapies. Dr. De Santis provides deep expertise across the hematology/oncology and immuno-oncology landscapes and this is supported by 4 years of clinical training and 5 years of translational oncology research.
Therapy Area & Subject Matter Expertise
Immuno-Oncology (Large & Small Molecules)
Generics & Biosimilars
Addressable Market Analysis
Car-T/Adoptive Cellular Therapies
Molecular Diagnostic
Advanced Forecasting
Immunology
Discounted Cash Flow Valuation
Physician Education
Pricing & Market Access
M&A Valuation And Analysis
Commercial Analytics
Dr. Neha Dalmia joined Molekule with >13 years of scientific and business experience, having a unique ability to synthesize complex datasets into actionable insights. She has >5 years of market research, business strategy, and competitive intelligence (CI) experience in diverse therapeutic areas including immunology, oncology, biosimilars, and CNS. 
She also brings significant experience regarding innovation for in vitro diagnostics, social media monitoring, and mentorship, having supported more than 60 startups in the medical devices and digital health field as part of the MedTech Innovator Accelerator, and having previously led development of PulseTraQ, within TheratraQ, building two service-based offerings for research on various social media platforms.
Therapy Area & Subject Matter Expertise
Oncology
Clinical Development
Forecasting & Modeling
Immunology
Diagnostics
CI Process Consulting & CI Training
Generics & Biosimilars
Sales Force Effectiveness
Digital Healthcare
Social Media Listening
Lifecycle Management
Michael started at Molekule in April 2022, and brings broad therapeutic experience from a prior role as a Senior Consultant at Kantar Health, where he built forecast models for pharma clients, conducted primary and secondary research, competitive intelligence.

Prior to joining Molekule, Michael was the Director of Forecasting, BD&L / Portfolio at Mallinckrodt Pharmaceutical’s Specialty Generics business. 
There, Michael’s role was a strategic one, suggesting and vetting product ideas for addition to Mallinckrodt’s generics pipeline, taking into account factors including IP protection and ANDA filers, generic price erosion and order of entry modeling, and utilization of products within the treatment landscape when projecting company NPV-adjusted net revenue. Opportunities were both organic and inorganic, including analysis of many 3rd party business development commercial ventures.
Therapy Area & Subject Matter Expertise
Forecasting
Biomarkers
Diabetes
Market Research
ADHD
Rare Genetic Diseases
Supply Chain
Oncology
CNS Disorders
Generics
Pain
Hypertension
Richa is an experienced life science professional specialized in providing strategic and competitive intelligence advisory. She has been trained in oncology and genetics and has deep knowledge of drug discovery and clinical development.
At Molekule Consulting, she is responsible for managing competitive market landscapes that inform clinical and commercial implications in hem-onc, cell therapy and immunology. Specifically, she triangulates real-time insights on CAR-Ts, bispecific antibodies, and other novel modalities through industry databases and primary sources at medical conferences, to shape the clients’ business and launch strategies.
Therapy Area & Subject Matter Expertise
Immunology
Hematology
Vaccines
Women’s Health
Neuroscience
Smart Devices
R&D Strategy
Primary Research
Data Analysis
Project Management
Clinical Development Strategy
Commercialization
Oncology
Landscape Assessment
Competitive Intelligence
A biophysicist by training, Dr. Brett Alcott is uniquely positioned as a biopharma industry subject matter expert and brings with him a deep appreciation for the importance of basic research in understanding disease mechanisms and improving human health. Brett’s academic research focused on the protein-lipid interplay underlying the fusion of membrane-enveloped viruses, such as influenza, Ebola and HIV, with their host cells. His work sought to isolate and characterize the fusion pore – a transient lipidic connection between virus and host and a crucial early intermediate in the infection process – using an experimental approach which combined a novel, nanoscale in vitro electrical technique (capable of inferring pore size with millisecond resolution) and radically coarse-grained molecular dynamics simulations.
Additionally, Brett developed a novel, robust single-cell fluorescence technique to report membrane fusion between cells expressing viral fusion proteins and bilayer nanodiscs of controllable size and chemical composition which could serve as a platform for future antiviral drug screens. A lifelong New Yorker, Brett holds a B.A. in Chemistry and Biochemistry from Cornell University, where he was a Cornell Presidential Research Scholar, and a Ph.D. in Biophysics from Columbia University (2017), where he was an NIH predoctoral fellow in Molecular Biophysics and an Exchange Scholar at Yale University.
Therapy Area & Subject Matter Expertise
Membrane biophysics & biochemistry
Molecular modeling & simulations
Computational Pharmacology
Virology
Nanobiology
Oncology
Drug Design
Biologics
Women’s Health
Go-to-Market Strategy
Clinical Development
Immunology
Sid started his career as a molecular biologist in the Translational Medicine Lab at ACTREC (India’s foremost cancer research hospital) where the team was trying to identify novel mechanisms for metastasis and ways to prevent it. However, he soon realized that a narrow focus - on a single target/ pathway is not enough and decided to move into consulting to get a more holistic/ bird’s eye view of things.

His background in Oncology due to his M.Sc. in Cancer immunology and strong understanding of the mechanics behind the various molecular pathways due to his research experience provided the base required to integrate with the commercial side. His education and experience in CI and market research have molded Sid into a well-rounded therapy area expert with a strong understanding of the developments and current trends in oncology.
Sid specializes in providing quick turnaround projects requiring science driven insights. He is exceptionally capable when it comes to handling requests from the new program/ development teams looking to focus or prioritize indications and combinations. As a team lead at Value Edge (now WNS Global Services), Sid was responsible for handling and maintaining working relationships and providing quality service to blue-chip pharma companies.
Therapy Area & Subject Matter Expertise
Asset Differentiation
Prioritization (Assets & Indications)
Solid & Hematological Tumors
Clinical & Preclinical Data Analysis
Competitive Intelligence
Infectious Disease & Antibiotics
Immunotherapy In Oncology
Sharon Rosaler began her career as an accountant at Ernst & Young before entering the private sector. Prior to her appointment to CFO, Sharon headed Molekule’s accounting department since 2016. Sharon’s deep background in healthcare accounting is underpinned by the development of financial relationships, raising capital, satisfying financial obligations, ensuring record control, merger and acquisitions, strategy, and due diligence evaluation. She holds a Bachelor’s Degree in Business Administration and a Masters of Accounting Degree from the University of Miami from 2004

crosscross-circle linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram